Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Dichlorphenamide (Daranide; Diclofenamide; Dichlofenamide) is a sulfonamide analog acting as a CAI/carbonic anhydrase inhibitor, it belongs to the meta-Disulfamoylbenzene class. Diclofenamide is an approved drug used to treat glaucoma and therapy-resistant epilepsy.
ln Vivo |
Male albino rabbits' intraocular pressure can be locally decreased by dichlorphenamide [1].
|
---|---|
Animal Protocol |
Animal/Disease Models: Male albino rabbit (about 2.5 kg)
Doses: Dichlorphenamide sodium 50 μL 10% aqueous solution or 2 mg/kg, 6 mg/kg Route of Administration: 50 μL eye drops or po (oral gavage) 2 mg/kg Or 6 mg/kg, 5 hrs (hrs (hours)). Experimental Results: Intraocular pressure diminished Dramatically 30 minutes after instillation into the eye. Intraocular pressure diminished 1 hour after oral administration. Drug concentration in the iris and ciliary body increased Dramatically. Drug concentration in the iris and ciliary body increased Dramatically. The concentration is Dramatically diminished. By instillation of serum compared to oral administration. |
References |
[1]. Kanski, J.J., Carbonic anhydrase inhibitors and osmotic agents in glaucoma. Carbonic anhydrase inhibitors. Br J Ophthalmol, 1968. 52(8): p. 642-3.
[2]. Rucquoy, M. and L. Sorel, Diclofenamide in the treatment of therapy-resistant epilepsy. Acta Neurol Belg, 1978. 78(3): p. 174-82. |
Molecular Formula |
C6H6CL2N2O4S2
|
|
---|---|---|
Molecular Weight |
305.16
|
|
CAS # |
120-97-8
|
|
Related CAS # |
Dichlorphenamide disodium;76382-13-3
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2770 mL | 16.3848 mL | 32.7697 mL | |
5 mM | 0.6554 mL | 3.2770 mL | 6.5539 mL | |
10 mM | 0.3277 mL | 1.6385 mL | 3.2770 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT00494507 | Completed Has Results | Drug: Dichlorphenamide (double-blind) | Hyperkalemic Periodic Paralysis Hypokalemic Periodic Paralysis |
University of Rochester | June 2007 | Phase 3 |
NCT00004802 | Completed | Drug: dichlorphenamide | Paralysis, Hyperkalemic Periodic Hypokalemic Periodic Paralysis |
National Center for Research Resources (NCRR) |
June 1992 | Phase 3 |